Antibodies

Scientists leverage the natural ability of antibodies to cross the blood-brain barrier and target proteins implicated in neurodegenerative disease.

Investigating antibodies produced by infectious diseases yields vaccines with broad-acting protection.

LIVE June 30th, 2021 at 2:30 PM ET

In this webinar, scientists will discuss the emergence of SARS-CoV-2 variants and strategies for monitoring, tracking, and mitigating SARS-CoV-2 escape variants.

LIVE June 22nd, 2021 at 2:30 PM ET

This webinar will explore recent discoveries about the way the immune system responds to SARS-CoV-2 infection.

Infectious diseases alter the traditional vaccine pipeline and spawn new approaches to antibody research and vaccine development.

LIVE May 20th, 2021 at 2:30 PM ET
In this webinar, Berkeley Lights scientists present a new platform for antibody discovery and cell line development that accelerates the identification and production of leading therapeutic molecules.

Therapeutic candidates retain binding to major COVID-19-causing “South African” variant

Inhalable Antibodies for SARS-CoV-2

The anti-CD117 antibody is being evaluated as a conditioning agent prior to blood stem cell transplantation

Two leading scientists call on health agencies to invest in broadly effective vaccines